Crolibulin, with the CAS number 1000852-17-4, is a synthetic compound that has been investigated primarily for its potential use in cancer therapy. It functions as a microtubule destabilizer, which disrupts the normal function of microtubules in cells, thereby inhibiting cell division and promoting apoptosis in rapidly dividing cancer cells. This mechanism of action is similar to that of other chemotherapeutic agents, but Crolibulin has been noted for its specificity and reduced toxicity to normal tissues. In preclinical studies, it has shown promise against various tumor types, including solid tumors. The compound is typically administered intravenously and has undergone various phases of clinical trials to assess its efficacy and safety profile. As with many investigational drugs, ongoing research is crucial to fully understand its pharmacokinetics, optimal dosing regimens, and potential side effects. Overall, Crolibulin represents a novel approach in the field of oncology, contributing to the development of targeted cancer therapies.

Crolibulin

1000852-17-4: Crolibulin, with the CAS number 1000852-17-4, is a synthetic compound that has been investigated primarily for its potential use in cancer therapy. It functions as a microtubule destabilizer, which disrupts the normal function of microtubules in cells, thereby inhibiting cell division and promoting apoptosis in rapidly dividing cancer cells. This mechanism of action is similar to that of other chemotherapeutic agents, but Crolibulin has been noted for its specificity and reduced toxicity to normal tissues. In preclinical studies, it has shown promise against various tumor types, including solid tumors. The compound is typically administered intravenously and has undergone various phases of clinical trials to assess its efficacy and safety profile. As with many investigational drugs, ongoing research is crucial to fully understand its pharmacokinetics, optimal dosing regimens, and potential side effects. Overall, Crolibulin represents a novel approach in the field of oncology, contributing to the development of targeted cancer therapies.

Crolibulin (EPC2407) is an inhibitor of small molecule tubulin polymerization.

CAS 1000852-17-4

Crolibulin

Crolibulin

Ref: TM-T15012

Crolibulin

Ref: 54-BUP08450